Top

Published in:

Open Access 01-12-2016 | Research

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

Authors: Panagiotis Alexopoulos, Lukas Werle, Jennifer Roesler, Nathalie Thierjung, Lena Sophie Gleixner, Igor Yakushev, Nikolaos Laskaris, Stefan Wagenpfeil, Philippos Gourzis, Alexander Kurz, Robert Perneczky, for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Published in: Alzheimer's Research & Therapy | Issue 1/2016

Abstract

Background

According to new diagnostic guidelines for Alzheimer’s disease (AD), biomarkers enable estimation of the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD dementia for patients with mild cognitive impairment (MCI). Nonetheless, how conflicting biomarker constellations affect the progression risk is still elusive. The present study explored the impact of different cerebrospinal fluid (CSF) biomarker constellations on the progression risk of MCI patients.

Methods

A multicentre cohort of 469 patients with MCI and available CSF biomarker results and clinical follow-up data was considered. Biomarker values were categorized as positive for AD, negative or borderline. Progression risk differences between patients with different constellations of total Tau (t-Tau), phosphorylated Tau at threonine 181 (p-Tau) and amyloid-beta 1–42 (Aβ₄₂) were studied. Group comparison analyses and Cox regression models were employed.

Results

Patients with all biomarkers positive for AD (N = 145) had the highest hazard for progression to dementia due to AD, whilst patients with no positive biomarkers (N = 111) had the lowest. The risk of patients with only abnormal p-Tau and/or t-Tau (N = 49) or with positive Aβ₄₂ in combination with positive t-Tau or p-Tau (N = 119) is significantly lower than that of patients with all biomarkers positive.

Conclusions

The risk of progression to dementia due to AD differs between patients with different CSF biomarker constellations.

Available only for authorised users

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. doi:10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentral

McKhann GM. Changing concepts of Alzheimer disease. JAMA. 2011;305:2458–9. doi:10.1001/jama.2011.810.CrossRefPubMed

Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier, Wiesje M. Alzheimer’s disease. Lancet. 2016. doi:10.1016/S0140-6736(15)01124-1.

Schoonenboom NSM, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78:47–54. doi:10.1212/WNL.0b013e31823ed0f0.CrossRefPubMed

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–13. doi:10.1002/ana.21610.CrossRefPubMedPubMedCentral

Troussiere AC, Wallon D, Mouton-Liger F, Yatimi R, Robert P, Hugon J, et al. Who needs cerebrospinal biomarkers? A national survey in clinical practice. J Alzheimers Dis. 2014;40:857–61. doi:10.3233/JAD-132672.PubMed

Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, et al. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord. 2010;29:491–7. doi:10.1159/000313534 .CrossRefPubMed

Mouton-Liger F, Wallon D, Troussiere A-C, Yatimi R, Dumurgier J, Magnin E, et al. Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric study. J Neurol. 2014;261:144–51. doi:10.1007/s00415-013-7160-3.CrossRefPubMed

Duits FH, Prins ND, Lemstra AW, Pijnenburg YAL, Bouwman FH, Teunissen CE, et al. Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic. Alzheimers Dement. 2015;11:523–32. doi:10.1016/j.jalz.2014.05.1753.CrossRefPubMed

10.

Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74:199–208. doi:10.1002/ana.23931.PubMedPubMedCentral

11.

Alexopoulos P, Grimmer T, Perneczky R, Domes G, Kurz A. Do all patients with mild cognitive impairment progress to dementia? J Am Geriatr Soc. 2006;54:1008–10. doi:10.1111/j.1532-5415.2006.00752.x.CrossRefPubMed

12.

Alexopoulos P, Grimmer T, Perneczky R, Domes G, Kurz A. Progression to dementia in clinical subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord. 2006;22:27–34. doi:10.1159/000093101.CrossRefPubMed

13.

Maioli F, Coveri M, Pagni P, Chiandetti C, Marchetti C, Ciarrocchi R, et al. Conversion of mild cognitive impairment to dementia in elderly subjects: a preliminary study in a memory and cognitive disorder unit. Arch Gerontol Geriatr. 2007;44 Suppl 1:233–41. doi:10.1016/j.archger.2007.01.032.CrossRefPubMed

14.

Ravaglia G, Forti P, Montesi F, Lucicesare A, Pisacane N, Rietti E, et al. Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. J Am Geriatr Soc. 2008;56:51–8. doi:10.1111/j.1532-5415.2007.01503.x.CrossRefPubMed

15.

Rozzini L, Chilovi BV, Conti M, Bertoletti E, Delrio I, Trabucchi M, Padovani A. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration. Int J Geriatr Psychiatry. 2007;22:1217–22. doi:10.1002/gps.1816.CrossRefPubMed

16.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. doi:10.1016/j.jalz.2011.03.008.CrossRefPubMedPubMedCentral

17.

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193–9. doi:10.1212/WNL.0b013e3181bc010c.CrossRefPubMedPubMedCentral

18.

Alexopoulos P, Kriett L, Haller B, Klupp E, Gray K, Grimmer T, et al. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer’s disease. Alzheimers Dement. 2014;10:684–9. doi:10.1016/j.jalz.2014.03.006.CrossRefPubMed

19.

Yakushev I, Muller MJ, Buchholz H-G, Lang U, Rossmann H, Hampel H, et al. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer’s disease. Curr Alzheimer Res. 2012;9:241–7.CrossRefPubMed

20.

Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230–8. doi:10.1212/WNL.0b013e3181e8e8b8.CrossRefPubMedPubMedCentral

21.

Vos SJB, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund L-O, et al. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology. 2013;80:1124–32. doi:10.1212/WNL.0b013e318288690c .CrossRefPubMed

22.

Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology. 2011;77:1619–28. doi:10.1212/WNL.0b013e3182343314.CrossRefPubMedPubMedCentral

23.

van Rossum IA, Vos SJB, Burns L, Knol DL, Scheltens P, Soininen H, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology. 2012;79:1809–16. doi:10.1212/WNL.0b013e3182704056.CrossRefPubMedPubMedCentral

24.

Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, van Berckel B, Barkhof F, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013;80:1048–56. doi:10.1212/WNL.0b013e3182872830.CrossRefPubMed

25.

Prestia A, Caroli A, Wade SK, van der Flier WM, Ossenkoppele R, van Berckel B, et al. Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement. 2015;11:1191–201. doi:10.1016/j.jalz.2014.12.001.CrossRefPubMed

26.

Jack CR, Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, et al. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol. 2015. doi:10.1016/S1474-4422(15)00323-3.PubMed

27.

Callahan BL, Ramirez J, Berezuk C, Duchesne S, Black SE. Predicting Alzheimer’s disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers. Alzheimers Res Ther. 2015;7:68. doi:10.1186/s13195-015-0152-z.CrossRefPubMedPubMedCentral

28.

Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W, et al. Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain. 2015;138:1327–38. doi:10.1093/brain/awv029.CrossRefPubMedPubMedCentral

29.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010;6:230–8. doi:10.1016/j.jalz.2010.03.008.CrossRefPubMedPubMedCentral

30.

Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011;76:69–79. doi:10.1212/WNL.0b013e318204a397.CrossRefPubMed

31.

Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, et al. Alzheimer’s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement. 2010;6:265–73. doi:10.1016/j.jalz.2010.03.013.CrossRefPubMedPubMedCentral

32.

Alexopoulos P, Roesler J, Thierjung N, Werle L, Buck D, Yakushev I, et al. Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2015. doi:10.1007/s00406-015-0628-7.PubMed

33.

Lee DD, Seung HS. Learning the parts of objects by non-negative matrix factorization. Nature. 1999;401:788–91. doi:10.1038/44565 .CrossRefPubMed

34.

Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche J-L, et al. Cerebrospinal fluid amyloid-beta 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther. 2015;7:30. doi:10.1186/s13195-015-0114-5.CrossRefPubMedPubMedCentral

35.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YAL, van Elk EJ, Scheltens P, van der Flier WM. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology. 2009;73:1353–8. doi:10.1212/WNL.0b013e3181bd8271.CrossRefPubMed

36.

Weih M, Sulimma A-K, Lehfeld H, Niklewski G, Sonnenberg M, Richter-Schmidinger T, et al. Comparison of patient therapy adherence of two structural different memory clinics. Fortschr Neurol Psychiatr. 2009;77:212–7. doi:10.1055/s-0028-1109069.CrossRefPubMed

37.

Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16. doi:10.1016/S1474-4422(12)70291-0.CrossRefPubMedPubMedCentral

38.

Degerman Gunnarsson M, Lannfelt L, Ingelsson M, Basun H, Kilander L. High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in alzheimer’s disease. Dement Geriatr Cogn Disord. 2014;37:196–206. doi:10.1159/000355556.CrossRefPubMed

39.

Prestia A, Caroli A, Herholz K, Reiman E, Chen K, Jagust WJ, Frisoni GB. Diagnostic accuracy of markers for prodromal Alzheimer’s disease in independent clinical series. Alzheimers Dement. 2013;9:677–86. doi:10.1016/j.jalz.2012.09.016.CrossRefPubMedPubMedCentral

40.

Mattsson N. CSF Biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385. doi:10.1001/jama.2009.1064 .CrossRefPubMed

41.

Ravaglia S, Bini P, Sinforiani E, Franciotta D, Zardini E, Tosca P, et al. Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer’s disease and vascular dementia. Neurol Sci. 2008;29:417–23. doi:10.1007/s10072-008-1023-1.CrossRefPubMed

42.

Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer’s disease intensity. Int J Geriatr Psychiatry. 2010;25:403–10. doi:10.1002/gps.2353.CrossRefPubMed

43.

Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry. 1999;46:750–5.CrossRefPubMed

44.

Duits FH, Teunissen CE, Bouwman FH, Visser P-J, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimers Dement. 2014;10:713–23.e2. doi:10.1016/j.jalz.2013.12.023.CrossRefPubMed

45.

Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, et al. A data-driven model of biomarker changes in sporadic Alzheimer’s disease. Brain. 2014;137:2564–77. doi:10.1093/brain/awu176.CrossRefPubMedPubMedCentral

46.

Jack CR, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron. 2013;80:1347–58. doi:10.1016/j.neuron.2013.12.003.CrossRefPubMedPubMedCentral

47.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. doi:10.1016/S1474-4422(13)70044-9.CrossRefPubMed

48.

Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A. Concordance and diagnostic accuracy of [11C]PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. 2015;45:1077–88.PubMed

49.

Perani D, Cerami C, Caminiti SP, Santangelo R, Coppi E, Ferrari L, et al. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Eur J Nucl Med Mol Imaging. 2016;43:499–508.CrossRefPubMed

50.

Gomar JJ. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer’s Disease Neuroimaging Initiative. Arch Gen Psychiatry. 2011;68:961. doi:10.1001/archgenpsychiatry.2011.96.CrossRefPubMed

51.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73:294–301. doi:10.1212/WNL.0b013e3181af79fb.CrossRefPubMedPubMedCentral

52.

Jack Jr CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging–Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765–75. doi:10.1002/ana.22628.CrossRefPubMedPubMedCentral

53.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. doi:10.1016/S1474-4422(14)70090-0.CrossRefPubMed

54.

Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol. 2012;71:266–73. doi:10.1097/NEN.0b013e31824b211b.CrossRefPubMedPubMedCentral

55.

Guo L-H, Alexopoulos P, Eisele T, Wagenpfeil S, Kurz A, Perneczky R. The National Institute on Aging–Alzheimer’s Association research criteria for mild cognitive impairment due to Alzheimer’s disease: predicting the outcome. Eur Arch Psychiatry Clin Neurosci. 2013;263:325–33. doi:10.1007/s00406-012-0349-0.CrossRefPubMed

56.

Vos SJB, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I, et al. Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice. PLoS ONE. 2014;9, e100784. doi:10.1371/journal.pone.0100784.CrossRefPubMedPubMedCentral

57.

del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012;6:419–30.

58.

Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, et al. Impact of harmonization of collection tubes on Alzheimer’s disease diagnosis. Alzheimers Dement. 2014;10:S390–4.e2. doi:10.1016/j.jalz.2013.06.008.CrossRefPubMed

Title: Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
Authors: Panagiotis Alexopoulos
Lukas Werle
Jennifer Roesler
Nathalie Thierjung
Lena Sophie Gleixner
Igor Yakushev
Nikolaos Laskaris
Stefan Wagenpfeil
Philippos Gourzis
Alexander Kurz
Robert Perneczky
for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Alzheimer's Research & Therapy / Issue 1/2016
Electronic ISSN: 1758-9193
DOI: https://doi.org/10.1186/s13195-016-0220-z

At a glance: The STEP trials

Springer Medicine

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Transcranial direct current stimulation as a memory enhancer in patients with Alzheimer’s disease: a randomized, placebo-controlled trial

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease

Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment

Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device

Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease

Brain perfusion in dementia with Lewy bodies and Alzheimer’s disease: an arterial spin labeling MRI study on prodromal and mild dementia stages